Recent NRBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:06:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 01:01:28 PM
- NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 11/07/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 01:30:23 PM
- NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 11/04/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 11:00:29 AM
- NeuroBo Pharmaceuticals to Participate in Investor Conferences in October • PR Newswire (US) • 10/01/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 12:07:00 PM
- NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 09/30/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 08:20:16 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/20/2024 08:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:10:30 PM
- NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 12:01:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/21/2024 08:02:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:08:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:01:18 PM
- NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:30:30 PM
- NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 08/13/2024 12:01:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/07/2024 12:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 12:30:17 PM
- NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 08/06/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 12:30:18 PM
- NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 • PR Newswire (US) • 07/30/2024 12:01:00 PM
FEATURED DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • Nov 7, 2024 2:16 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • Nov 7, 2024 8:48 AM
FEATURED SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • Nov 7, 2024 7:00 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM